Highlights Newsletter 1 This newsletter presents you the following key sessions: Watch the video interview with professor Corey Langer about the updated results from KEYNOTE-021 cohort G: a randomized, phase II study of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC Adding abiraterone acetate and prednisone or docetaxel and prednisone to long-term androgen deprivation therapy in patients with high-risk prostate cancer: both effective treatment options The PI3K inhibitor taselisib increases the response rate when added to neoadjuvant endocrine therapy in patients with ER+/HER2- early breast cancer Promising response rates with pembrolizumab in metastatic gastric cancer Delayed disease progression with the PD-L1 inhibitor durvalumab in patients with locally advanced, unresectable stage III lung cancer